CA2436374A1 - Water-soluble compositions of bioactive lipophilic compounds - Google Patents

Abstract

Water-soluble compositions comprising a lipophilic compound and a solubilizi ng agent of the general formula: {X-OOC-[(CH2)n-COO]m}p-Y (I) wherein: X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p i s 1 or 2, m is 0 or 1, and n is an integer greater than or equal to 0 are disclosed. The lipophilic compound is preferably selected from the group consisting of water-insoluble ubiquinones, ubiquinols, vitamins, provitamins , polyene macrolide antibiotics, and mixtures thereof. The hydrophobic moiety is preferably a sterol or a tocopherol and the hydrophilic moiety is preferably a polyalkylene glycol. In some embodiments, the sterol is cholesterol or sitosterol, the tocopherol is .alpha.(+)-tocopherol, the polyalkylene glycol is a polyethylene glycol or its methyl monoether having an average molecular weight between 400 and 1000, p is equal to 1 or 2, m is equal to 0 or 1 and n is an integer between 2 and 18.

Description

WATER-SOLUBLE COMPOSITIONS OF BIOACTIVE LIPOPHILIC
COMPOUNDS
FIELD OF THE INVENTION
The present invention relates to water-soluble compositions of bioactive lipophilic compounds, to compounds useful for the preparation of such compositions, to methods of preparing such compounds and compositions, and to the use of such compositions as therapeutics and cosmetics.
BACKGROUND OF THE INVENTION
Many bioactive compounds are highly lipophilic (hydrophobic), meaning that they are soluble in lipids (oils) and some organic solvents, while being substantially insoluble or only sparsely soluble in water. The lack of solubility of a bioactive compound in aqueous media is an important factor limiting its therapeutic applications, making difficult an efficient administration of the compound to a patient. When administered in the form of an oil solution or some kind of water and/or oil suspension or emulsion, lipophilic compounds usually 2 o show a poor bioavailability, meaning a low concentration and a long build-up time of the compound in the systemic circulation. This lack of bioavailability is usually independent of the administration route (topical, oral, or parenteral).
Various approaches to overcoming this limitation are known in the prior 2 5 art. One known approach consists of dissolving a lipophilic compound in a water-miscible organic solvent, such as ethanol or propylene glycol. When such a solution is admixed with blood or gastrointestinal fluids, however, the lipophilic compound usually precipitates as a solid or liquid emulsion, with a resulting low bioavailability. Furthermore, for many lipophilic compounds no organic, water-3 o miscible solvents exist. Another approach consists of incorporating lipophilic compounds into various compositions, frequently inhomogeneous, multiphase emulsions, containing oils and solvents in combination with surfactants. These compositions may improve the bioavailability of the compound without significantly increasing its solubility in aqueous media, but are normally suitable only for a particular administration form, usually for topical applications.
Such compositions, which may also induce a protective immune response in mammals, are of little value for therapeutic uses where administration of the compound by ingestion or injection is necessary and where an aqueous solution or a water-soluble solid composition is frequently the only acceptable administration form.
~o Several approaches to preparing homogenous aqueous solutions of lipophilic bioactive compounds are also known in the prior art. One method consists of preparing a derivative or an analog of a lipophilic compound having a better solubility in water than the original compound. In the simplest case, this ~5 derivative may be a water-soluble salt of the compound, which salt usually retains the original biological activity, but this approach is applicable only to compounds having acidic or basic properties. If more substantial modifications are introduced into the original compound to improve its solubility, a decrease or even a complete loss of the original bioactivity of the compound is frequently 2 0 observed.
Another method of solubilization consists of preparing a water-soluble derivative capable of ' liberating the original bioactive compound under physiological conditions. Such derivatives, also known as pro-drugs, usually 2 5 improve bioavailability of.the compound and may also ensure a targeted delivery of the compound or its sustained release over a period of time. However, this approach usually relies on the presence of certain functional groups in the original compound, so it is not universally applicable. In addition, synthetic methods of improving solubility of a compound by chemical modifications are 3 o relatively complicated and expensive.

Still another approach to solubilization of bioactive lipophilic compounds relies on formation of water-soluble complexes. An example are complexes with amphipathic compounds containing moieties of two opposing solubility tendencies (lipophilic and hydrophilic). Such compounds are often soluble both in organic solvents and in water, so that the solubilization is usually achieved by dissolving a bioactive lipophilic compound and an amphipathic compound in a suitable water-miscible organic solvent and diluting the solution with water.
In some cases the organic solvent is partially or entirely removed from the original or water-diluted solution by evaporation or lyophilization and the concentrate s o reconstituted with a suitable aqueous medium, without precipitation of the water-insoluble lipophilic compound. When the auxiliary organic solvent cannot be completely removed from the composition, this solvent must be pharmaceutically acceptable, which limits the choice of applicable solvents.
15 Bioactive lipophilic compounds in need of solubilization belong to various therapeutic categories, such as vitamins (e.g., Vitamin E), antibiotics, in particular macrolide polyene antibiotics (amphotericin-B, nystatin, candicidin), free radicals scavengers (e.g., tocopherols, ubiquinones), immunosuppressants (e.g., cyclosporine), etc. Various approaches to achieve the solubility and 2 o improve the bioavaiiability of these and other lipophilic compounds are known in the prior art, including formation of water-salubie complexes.
US patent No. 5,686,110 discloses water-soluble complexes of water-insoluble compounds, including amphotericin-B and cyclosporine, with a 25 polyalkylene oxide polymers end-capped with an alkyl or olefinic group, which polymers are soluble both in water and in organic solvents. The water-soluble complexes, which are formed only in the presence of an auxiliary organic solvent, are lyophilized and reconstituted with a buffer solution. The reconstituted aqueous solutions show only a limited stability, depending mostly on the pH of 3 o the solution. Furthermore, the use of methoxypolyethylene glycol polymers of relatively high molecular weight (2,000 to 5,000) as preferred solubilizing agents increases the amount by weight of polymer necessary for solubilization of the bioactive compound.
US 5,798,333 discloses a homogenous, water-soluble composition (concentrate) of cyclosporine, which can be diluted with an aqueous solution without precipitation of cyclosporine. The concentrate comprises cyclosporine and tocophersolan (polyoxyethanyl-a-tocopheryl succinate, TPGS) dissolved in a hydrophilic organic solvent, such as propylene glycol. Solvent-free compositions are not disclosed, as they would likely be unstable or inhomogeneous.
WO 96/17626 discloses water-soluble compositions of ubiquinones comprising polyoxyethanyl-cholesteryl sebacate (PCS) as a solubilizing agent.
A
ubiquinone, in particular Coenzyme Quo, is solubilized by dissolving both Coenzyme Q~o and PCS in tetrahydrofuran at an approximate molar ratio of 1:3 and diluting this solution with water. The solution is then evaporated to dryness under reduced pressure and reconstituted with a suitable bufFer solution.
Coenzyme Q~n (CoQ~o) is a natural compound whose therapeutic potential has been recently recognized for a number of disorders, including 2 o congestive heart failure, muscular distrophy, periodontal disease, correction of drug-induced deficiencies, and immune restoration (AIDS, allergies), to name a few. Coenzyme Quo is also of great interest to cosmetic industry, since it can be included into cosmetic preparations as agenfi slowing down natural skin ageing processes. The biological activity of Coenzyme Quo is believed to be linked to its ability to act as an antioxidant and free radical scavenger protecting integrity of cell membranes and to offset the inability of diseased cells to manufacture sufficient energy for cellular repair, by stimulating mitochondrial respiration and production of ATP. For effectiveness in both clinical and cosmetic applications, preparations of Goenzyme Quo with high bioavailability and solubility in aqueous 3 o media are usually required.

Even though various methods of improving solubility of lipophilic compounds, such as Coenzyme Quo, in aqueous media are known in the prior art, they are not equal in terms of simplicity, scope of applicability, stability of the prepared formulations, etc. The present invention provides a new method of solubilization of lipophilic compounds, which is free of many prior art drawbacks and limitations.
SUMMARY OF THE INVENTION
so According to one aspect, the present invention provides a water-soluble composition comprising a lipophilic compound and a solubilizing agent of the general formula:
~X-OOC-~(CH2)n-COO]n, ~p Y (I) wherein:
X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, 2 o m is 0 or 1, and n is an integer greater than or equal to 0.
The lipophilic compound is preferably selected from the group consisting of ubiquinones, ubiquinols, vitamins, provitamins, polyene macrolide antibiotics, and mixtures thereof. The hydrophobic moiety is preferably a sterol or a tocopherol and the hydrophilic moiety is preferably a polyalkylene glycol. In preferred embodiments, the sterol is cholesterol or sitosterol, the tocopherol is a-(+)-tocopherol, the polyalkylene glycol is a polyethylene glycol or its methyl monoether having an average molecular weight between 400 and 1000, p is 3 o equal to 1 or 2, m is equal to 0 .or 1 and n is an integer between 2 and 18.

According to another aspect of the invention, a water-soluble composition comprising a bioactive lipophilic compound and a solubilizing agent of the general formula {X-OOC-[(CH2)"-COO]m~~,-Y
wherein: p is 1 or 2, mis0or1,and n is an integer in the range O <_ n _< 18 X is a residue of a hydrophobic moiety selected from the group s o consisting of cholesterol, 7-dehydrocholesterol, campesterol, sitosterol, ergosterol, stigmasterol, and a-,[i-, y-, and d-tocopherols and derivatives thereof, Y is a residue of a hydrophilic moiety,selected from the group consisting of polyalcohols, polyethers, polyanions, polycations, polyphosphoric acids, 15 polyamines, polysaccharides, polyhydroxy compounds, polylysines and derivatives thereof, provided that:
when p and m are equal to 1 and the hydrophobic moiety is (+)-a-tocopherol, n is not equal to 2.
2 o According to another aspect, the invention provides a method of preparation and purification of a water-soluble composition comprising a solubilizing agent of the general formula (I), in the presence or in the absence of an auxiliary organic solvent. The solubilization is achieved by dissolving a water-insoluble lipophilic compound and a solubilizing agent in a water-miscible organic solvent, diluting 2 5 the solution with water, and removing the organic solvent and optionally a part of water under reduced pressure. Alternatively, a lipophilic compound and solubilizing agent can be admixed directly in a predetermined molar ratio and heated to a temperature higher than the their respective melting points, to form a water-soluble composition in the form of a clear melt, which can be then diluted with an aqueous solution to a desired concentration. The water-soluble composition may be additionally purified by dissolving it in a small amount of water, heating the solution until the composition separates as a clear liquid phase, and removing the separated composition from the solution while keeping the temperature of the solution substantially unchanged.
According to still another aspect, the invention provides pharmaceutical or cosmetic formulations comprising a water-soluble composition of a lipophilic compound and a solubilizing agent of formula (I).
According to yet another aspect, the invention provides novel solubilizing agents of formula (I) and methods of their preparation and purification.
According to a further embodiment of the invention, a method is provided for the treatment of a fungal infection in humans or warm-blooded animals in need of such treatment, comprising administering to such human or warm-blooded animal, a therapeutically effective amount of a water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and 2 o polyoxyethanyl-a-tocopheryl sebacate, and a macrolide polyene antibiotic , formulated in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1, in conjunction with a pharmaceutically effective carrier or excipient.
According to a yet further embodiment of the invention, a water-soluble 2 5 composition is provided, comprising, a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-a-tocopheryl sebacate, and a macrolide polyene antibiotic, formulated in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1.

According to a still further embodiment of the invention, a method is provided for preparing a water-soluble composition, comprising the steps of, (a) dissolving the antibiotic and the solubilizing agent in a water-miscible organic solvent, in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1, (b) removing from the solution the organic solvent to achieve a desired concentration of the water soluble composition, (c) dissolving the composition in water, and Zo (d) drying.
According to a yet further embodiment of the invention, a method is provided for delivery of a-tocopherol to humans or warm-blooded animals in z5 need thereof, comprising administering to such human orwarm-blooded animal, an effective amount of a water-soluble form of vitamin E.
PTS is a water-soluble form of vitamin E. We have found that in the body of an animal, water-soluble forms of vitamin E, such as PTS, get hydrolysed and 2 o are systemically converted back to a-tocopherol, an active non-toxic form of vitamin E. Accordingly, PTS can itself be administered to an animal in need thereof, as a means for delivery of active non-toxic vitamin E.
According to a yet further embodiment of the invention, a water-soluble 2 s composition is provided, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-a-tocopheryl sebacate, and a compound having a high content of polyunsaturated fatty acids and derivatives thereof.
Derivatives include mono-, di- and tri- glycerides and their aliphatic esters. Examples of s such compounds include fish oils, plant oils and other plant extracts. Further examples of such compounds can be found in the literature in B. Fitch Haumann: Alternate Sources for n-fatty acids in: Inform - International news on fats, oils and related materials (1998) vol. 19 no. 12, p. 1108, and in G.
Fernandes et al. Role of omega-3 fatty acids in health and disease. In:
Nutrition Research (1993) vol. 13, 19-45, the disclosures of which are incorporated herein by reference.
According to a still further embodiment of the invention, a water-soluble z o composition is provided, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-a-tocopheryl sebacate, and a bioactive lipophilic compound selected from the group consisting of a terpene and a terpenoid.
15 We have now solubilized in water a-tocopheryl acetafie, a synthetic form of vitamin E, using various solublizing agents including PTS-600 and PTS-400.
The ratio of solubilizing agent to a-tocopheryl -acetate was in the range of 2:1 to 5.5:1 w/w. Water-soluble compositions were obtained using either the 2 o awaiting solvent eg THF method, or the direct admixing method described above.
Tocotrienols are water-insoluble tocopherol derivatives, useful as antioxidants. We have now made a pegylated form of a tocotrienol 2 5 polyoxyethanyl tocotrienyl sebacate (PTrienS-600), which is useful as a solubilizing agent. The method involves dissolving a tocotrienol and triethylamine in a water-misable organic solvent e.g. ethyl acetate, and reacting the solution with sebacoyl chloride, followed by pegylation. See examples 39 and 32. It will be appreciated that this invention is also applicable to other tocotrienols such as 3 o those described in www.eastman.com/online publications, Nutriene tocotrienols.
Publication v-24,(1998), the disclosure of which is incorporated herein by reference. We have also dissolved the tocotrienols in water, using a solubilizing agent eg. PTS-600 or a pegylated tocotrienols polyoxycthanyltocotrienyl sebacate eg (PtrieneS-600.) (see example 32). The ratio of solubilizing agent to tocotreinols is about 5.5:1 w/w. The water-soluble compositions are obtained using either the auxiliary solvent method, or the direct admixing methods described above.
We have also shown that CoQ~O can be water solublized using either PTS-400, or pegylated derivatives of tocotrienols, such as to polyoxyethanyltocotrienyl sebacate (PtriensS-600) as solubilizing agent.
The ratio of solubilizing agent to CoQ~o was in the range 2.5:1 to 3.5:1. The direct admixing method described above was used. See example 33.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a graph showing the toxicity of various solubilizing agents.
Fig. 2 is a graph showirig the bioavailability of CoQ~o in various water-soluble compositions.
Fig. 3 is a graph showing the effect of PTS-CoQ~o composition on cellular ATP
level in NT2 cells.
Fig. 4 is a graph showing the protective effect of PTS-CoQ~o composition against 2 5 hypoxia in NT2 cells.
Fig. 5 is a graph showing the effect of PTS-CoQ~o and PTS-Vitamin E
compositions on the viability of hjrpoxia-treated NT2 cells.
DETAILED DESCRIPTION OF THE INVENTION

The invention provides a method of solubilization of substantially water-insoluble, bioactive lipophilic compounds, by providing 'a water-soluble composition comprising the lipophilic compound and a solubilizing agent of the following general formula:
~X-OOC-~(CH2)"-GOO]", }p-Y (I) wherein:
1 o X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, m is 0 or 1, and n is an integer greater than or equal to 0.
The hydrophobic moiety of the solubilizing agent is a hydrophobic (lipophilic) molecule having an esterifiable hydroxy group e.g. a sterol or a-tocopherol, in particular cholesterol, 7-dehydrocholesterol, campesterol, sitosterol, ergosterol, stigmasterol, or an a-, ~3-, y-, or ~-tocopherol.
Cholesterol 2 o and sitosterol are preferred sterols, sitosterol being particularly preferred. a-(+)-tocopherol and a-(~)-tocophero( are exemplary tocopherols, a-(+)-tocopherol (vitamin E) being preferred. The residue of the hydrophobic moiety is the entire hydrophobic molecule, except for ifs esterified hydroxy group, such as 3-~i-hydroxy group of cholesterol or sitosterol or 6-hydroxy group of a-tocopherol.
The hydrophilic moiety of the solubilizing agent is a hydrophilic molecule having an esterifiable hydroxy or carboxy group, for example, selected from the group consisting of polyalcohols, polyethers, polyanions, polycations, polyphosphoric acids, polyamines, polysaccharides, polyhydroxy compounds, 3 o polylysines, and derivatives thereof. Of those, polyethers are preferred, polyalkylene glycols being particularly preferred. The term "polyalkylene glycol"

includes polymers of lower alkylene oxides; in particular polymers of ethylene oxide {polyethylene glycols) and propylene oxide {polypropylene glycols), having an esterifiable hydroxy group at feast at one end of the polymer molecule, as well as derivatives of such polymers having esterifiable carboxy groups. The residue of the hydrophilic moiety is the entire hydrophilic molecule, except for its esterified hydroxy or carboxy group or groups! such as terminal hydroxy groups of a polyethylene glycol molecule.
Suitable polyethylene glycols may have a free hydroxy group at each so end of the polymer molecule, or may have one hydroxy group etherified with a lower alkyl, e.g., a methyl group. Also suitable for the practice of the invention are derivatives of polyethylene glycols having esterifiable carboxy groups.
Polyethylene glycols are commercially available under the trade name PEG, usually as mixtures of polymers characterized by an average molecular weight.
15 Polyethylene glycols having an average molecular weight from about 300 to about 5000 are preferred, those having an average molecular weight from about 600 to about 1000 being particularly preferred.
Compounds of formula (I) for which m is equal to 1 can be regarded as 2 o diesters of an alkanediofc acid of the general formula HOOC-(CH2)"-COOH.
For the practice of the present invention, alkanedioic acids with n from 0 to 18 are preferred, those with n from 6 to 10 being particularly preferred. Sebacic acid (n=8) is most particularly preferred.
2 s ~ Bioactive lfpophilic compounds which can be solubilized using solubilizing agents of the present invention belong to a variety of therapeutic and chemical categories and include ubiquinones, ubiquinols, sterols, vitamins, provitamins and macrolide polyene antibiotics.
3 o Preferred ubfquiniones and ubiquinols are those of the formula:

H _ wherein R is CH3 .
O OH
CH30 CH3 ~ CH30 ~ CH3 ~ or CH30 ~ ~ CH30 ~ w O . OH
and k is an integer of from 6 to 12. Those with k equal to 10 (ubiquinone-50 or Coenzyme Quo and ubiquinol-50 or reduced Coenzyme Quo, respectively) are particularly preferred.
Cholesterol, sitosterol, ergosterol and 7-dehydrocholesterol are preferred sterols. Vitamins A, D, E, and K are preferred vitamins and provitamin A (~i-carotene) is a preferred provitamin. Amongst macrolide polyene antibiotics, amphotericin-B, nystatin, and candicidin are preferred.
to The water-soluble compositions of the present invention contain a bioactive lipophilic compound and a solubilizing agent in a molar ratio of approximately 1:1 to 1:5. The molar ratio of about 1:2 is preferred. The upper limit of the molar ratio is not critical, and the solubilizing agent can be used in any excess. This is not desirable, however, as increasing the amount of the solubilizing agent decreases the concentration of the active ingredient in the composition and in its aqueous solutions.
The water-soluble compositions of the present invention can be prepared 2 0 by two different procedures, either in the presence or in the absence of an auxiliary organic solvent. In the first case, a lipophilic compound and a solubilizing agent are first dissolved in a predetermined molar ratio in a water-miscible organic solvent and this solution is then diluted with a predetermined amount of water, without precipitation of the lipophilic compound. The organic solvent and water are then removed by evaporation under reduced pressure. A
volatile organic solvent is usually removed first, followed by water, in which case the amount of water removed from the solution may be controlled, to achieve a desired concentration of the water-soluble composition in the remaining concentrate. Alternatively, both the organic solvent and water are removed by evaporation, and the waxy residue is reconstituted with a suitable aqueous medium (such as water, physiological saline, or a buffer solution), to provide a clear~aqueous solution.
The organic solvent used is in the above procedure should be a good solvent for both the lipophilic compound and the solubilizing agent and has to be so miscible with water. If a wafer-soluble composition is to be used in a pharmaceutical formulation, this solvent should be also pharmaceutically acceptable, as the removal of the solvent by evaporation may not always be possible. Examples of solvents suitable for the practice of the invention are tetrahydrofuran, ethanol, ethylene glycol, propylene glycol, and acetic acid.
Solvents with a low boiling point, such as tetrahydrofuran, are preferred.
The amount of the organic solvent is not critical, and is equal to or greater than the minimum amount of solvent necessary to dissolve the given amounts of the lipophilic compound and solubilizing agent. The amount of water used forthe 2 o dilution is also not critical, and is preferably between 10 to 25 times the volume of the organic solverit.
An alternative procedure for preparing water-soluble compositions according to the invention consists of preparing first a mixture of a lipophilic compound and a solubilizing agent in a predetermined molar ratio. This mixture is then heated to a temperature higher than the respective melting points of the lipophilic compound and the solubilizing agent, for a time necessary to obtain a clear melt, which process can be seen as a dissolution of the lipophilic compound in the solubilizing agent. The melt so obtained can be reconstituted 3 o with a predetermined amount of a suitable aqueous medium, to provide a clear aqueous solution of a desired concentration. This method of preparing water-soluble compositions of the invention is preferred, as it is simpler and avoids limitations of the procedure that relies on an auxiliary organic solvent, such as the pharmaceutically acceptable character of the solvent required for most applications.
The ability of solubilizing agents of the present invention to dissolve lipophilic compounds in the absence of an auxiliary organic solvent can be used for preparing water-soluble forms of bioactive compounds, in particular Coenzyme Quo, without purifying it by crystallization after synthesis, thus 1o reducing the overall cost of preparing water-soluble compositions of this compound.
Many compositions of the present invention show a decreasing solubility in water with increasing temperature of the solution. This provides an alternative method of isolation andlor purification of such compositions. Forthe purpose of purification, the composition is dissolved in water at a ratio of the composition to water not exceeding 1:2 by volume and the solution is heated, for example in a boiling water bath, for a time necessary to achieve the separation of the water-soluble composition as a liquid phase, usually a few minutes. The oily phase is 2 o then separated from the hot solution, while keeping the temperature of the solution substantially unchanged, as cooling of the solution would increase the solubility of the composifiion and result in a reduced yield of the recovery.
A
speedy separation of the oily phase to avoid the cooling can be achieved, for example, by centrifugation.
The water-soluble compositions of the present invention have a waxy consistence and may be difficult to manipulate in this highly concentrated form.
To make them more easily processabie as solids, they may be combined with a suitable solid, water-soluble additives, such as vitamin C, gelatin, a protein 3 o supplement, or a polyethylene glycol. In the latter case, a polyethylene glycol having an average molecular weight greater than about 5000 is preferred. The ratio of the composition and the additive is not critical, but will be usually limited to avoid an unnecessary dilution of the active ingredient by the additive.
Such solid composition are particularly useful for the preparation of certain dosage forms of bioactive compounds, such as tablets or granulates.
The compositions of the present invention show an excellent solubility in water and allow the preparation of aqueous solutions of almost any concentration. As the concentrated solutions can be diluted with an aqueous medium in any proportion and over a wide range of pH conditions without 1o precipitation of the lipophilic compound, the solubility of the compound is maintained under physiological conditions, for example after an oral or parenteral administration of the composition. This normally results in an improved bioavailability of the compound.
The compositions of the present invention and aqueous solutions thereof show an excellent stability over long periods of time (several months at room temperature, at least one year when refrigerated, or indefinitely when frozen) and over wide ranges of temperature and pH conditions (temperatures from 80°C to 120°C, pH from 2.0 to 8.0). Aqueous solutions can be repeatedly frozen 2 o and thawed without any perceptible degradation. The stability under high temperature conditions allows an easy sterilization of the solutions, without compromising the solubility of the active ingredient.
The water-soluble compositions of the present invention can be easily incorporated into pharmaceutical or cosmetic formulations, which are then charcterized by an improved bioavailability of the lipophilic active ingredient.
Such formulations may further contain additional active ingredients and/or a pharmaceutically or cosmetically acceptable additives or vehicles, including solvents, adjuvants, excipients, sweeteners, fillers, colorants, flavoring agents, 3 0 lubricants, binders, moisturizing agents, preservatives and mixtures thereof. The formulations may have a form suitable for a topical (e.g., a cream, lotion, gel, ointment, dermal adhesive patch), oral (e.g., a capsule, tablet, caplet, granulate), or parenteral (e.g., suppository, sterile solution) administration. Among the acceptable vehicles and solvents that may be employed for administration by injection are water, mildly acidified water, Ringer's solution and isotonic sodium chloride solution.
Among water-soluble compositions and pharmaceutical and cosmetic formulations, those comprising Coenzyme Quo are of particular interest.
Coenzyme Quo is a natural compound whose therapeutic potential has been Zo recently recognized for a number of conditions and disorders related to mitochondrial dysfunctions and/or tissue damage caused by free radicals and oxidants. These include, but are not limited to: cardiovascular diseases (e.g., congestive heart failure), muscular disorders (e.g., muscular dystrophy), mitochondrial encephalomyolopaties (i.g., MELAS, KSS), neurodegenerative disorders (e.g., Alzheimer', Parkinson's, Huntington's diseases), restoration of immune deficiencies caused by drugs or infections (AIDS, allergies, cancer).
Of particular interest is the clinical use of Coenzyme Quo to minimize tissue damage resulted from ischemia/reperfusion (e.g., stroke, head trauma, angioplasty, organ transplantation, surgery in general). Another area of interest is the use of 2 o Coenzyme Quo in therapy as adjuvant, for example for infectious diseases, in combination with cholesterol-lowering drugs for the treatment of hypercholesteremia, or in combination with chemotherapeutic agents in the treatment of cancers. Coenzyme Quo is also of great interest to cosmetic industry, as an agent slowing down natural skin ageing processes. Water-soluble compositions comprising a macrolide polyene antibiotic, such as amphotericin-B, nystatin, or candicidin, are of particular interest for the treatment of fungal infections, including fungal infections in immunocompromised patients.
Bioactive lipophilic compounds in the form of a water-soluble composition 3 o according to the present invention may be administered to a warm-blooded animal, particularly a human, in need of the prophylaxis or therapy. The dose of m a bioactive lipophilic compound and the corresponding dose of its water-soluble composition for treating the above-mentioned diseases or disorders vary upon the manner of administration, the age, sex, the body weight of the subject, and the condition being treated, and will be ultimately decided by the attending physician or veterinarian. Such an amount of the bioactive compound in the form of its water-soluble composition as determined by the attending physician or veterinarian is referred to herein as a "therapeutically effective amount".
The biological activity of Coenzyme Quo is believed to be linked to its 1 o ability to act as an antioxidant and free radical scavenger protecting integrity of cell membranes and to offset the inability of diseased cells to manufacture sufficient energy for cellular repair, by stimulating the mitochondrial respiration and production of ATP. For effectiveness in both clinical and cosmetic applications, preparations of Coenzyme Quo with high bioavailability and solubility in aqueous media are normally desirable.
Most pharmaceutical and cosmetic formulations proposed to date for Coenzyme Quo suffer from a number of drawbacks, such as the use of components causing an undesirable immune response when administered 2 o parenterally or gastric disorders when administered orally. Some formulations are stable only over a narrow range of pH values and most are characterized by a poor bioavailability of the active component (Coenzyme Quo). In particular, there are ~no reliable formulations for intravenous administration of Coenzyme Quo, as there are no formulations universally applicable to topical, oral, and 2 5 parenterai administration routes. The water-soluble compositions of the present invention comprising Coenzyme Quo are free of the above drawbacks and can be incorporated into pharmaceutical formulations suitable for all administration routes, topical, oral, and parenteral, which are stable and characterized by a good solubility and bioavailability of the active component.
The invention further provides novel solubilizing agents of the general formula ~X-OOC-[(CH2)"-COO]~, )p-Y (L) wherein: p is 1 or 2, m is 0 or 1, and n is an integer in the range of O<_n<_18, X is a residue of a hydrophobic moiety selected from the group consisting of cholesterol, 7-dehydrocholesterol, so campesterol, sitosterol, ergosterol, stigmasterol, and a-,~3-, y-, and ~-tocopherols and derivatives thereof, Y is a residue of a hydrophilic moiety, selected from the group consisting of polyalcohols, polyethers, polyanions, polycations, polyphosphoric acids, polyamines, 15 polysaccharides, polyhydroxy compounds, polylysines and derivatives thereof, provided thafi:
2 0 - when p and m are both equal to 1 and the hydrophobic moiety is a-(+)-tocopherol, n is not equal 2, Compounds excluded by the proviso are known in the prior art, in particular polyoxyethanyl-cholesteryl sebacate (PCS) and polyoxyethanyl-a-2 5 tocopheryl succinate (TPGS). However, PCS was only disclosed previously as a solubilizing agent for CoQ~o, that is, in our previously published PCT
application no. V11096/17626.
The compounds of formula (I) can be prepared by standard methods of 3 o synthetic organic chemistry, well known to those skilled in the art. In particular, compounds where p is equal to 1 or 2 and m is equal to 1 can be prepared by reacting a compound of the general formula X-OH with a compound of the general formula Z-OC-(CH2)n-CO-Z, where Z is a leaving group, and further reacting the product so obtained with a compound of the general formula HO-Y-OR, wherein R is hydrogen or an alkyl, and X, Y and n are as defined s hereinbefore. Halogens, in particular CI and Br, are preferred as the leaving group Z. Hydrogen and a lower alkyl (C~ - C4) are preferred for R.
Many solubilizing agents of formula (I) show a decreasing solubility in water with the increasing temperature of the solution, which provides a z o convenient method of purification of these compounds. The steps and conditions of the purification process are substantially the same as those discussed above for the purification of water-soluble compositions of the invention.
Various aspects of the present invention wilt be further illustrated by the 15 following non-limiting examples.
EXAMPLES.
The following abbreviations are used throughout the Examples:
CoQ10, CoQ~o - Coenzyme Quo PCS - polyoxyethanyl-cholesteryl sebacate PTS - polyoxyethanyl-a-tocopheryl sebacate PSS - polyoxyethanyl-sitosteryl sebacate PTD - polyoxyethanyl-a-tocopheryl dodecanodioate PTSr - polyoxyethanyl-a-tocopheryl suberate PTAz - polyoxyethanyl-a-tocopheryl azelaate TPGS - polyoxyethanyl-a-tocopheryl succinate 3 o A number following one of the above abbreviations (e.g., PCS-600) indicates an average molecular weight of the polyoxyethanyl moiety of the compound. A

number fiollowed by Me abbreviation (e.g., PTS-750Me) indicates a polyoxyethanyl moiety capped with a methyl group (methoxypolyoxyethanyl).
Examples 1 and 2 illustrate methods of preparation of solubilizing agents of the present invention.
Example 1. Preparation of polyoxyethanyl-sitosteryl sebacate (PSS-600) 0.83 g of b-sitosterol (Sigma Chem. Co., product #S-5753, approximately 60%) was dissolved in 3 ml of dry toluene at 40°C, followed by addition of 1.33 mmole of triethylamine (TEA). 1.33 mmole of sebacoyl chloride dissolved in 2 ml of dry toluene was than added (dropwise, while stirring, and under anhydrous conditions) to the b-sitosterol-TEA solution. The reaction was carried out for min at room temperature, at which time 2 mmole of PEG-600 (polyethylene glycol, Sigma Chem. Co.; product # P-3390) and 2.66 mmole of TEA dissolved in 3 ml of dry toluene were added dropwise to the reaction mixture. The reaction was continued with stirring for additional 20 min at room temperature and the reaction mixture was extracted four times with 3 ml each time of saturated solution of NaCI. The toluene was removed under reduced pressure leaving a 2 o waxy residue. This product was dissolved in 15 ml of water and water-insoluble materials removed by filtration. The filtrate was lyophilized, yielding 0.8 g of pale - yellow waxy product (PSS-600). The same method was used for the preparation of polyoxyethanyl-cholesteryl sebacate (PCS-600).
Example 2. Preparation of polyoxyethanyl-a-tocopheryl sebacate (PTS-2 5 600) A solution of 1 mmole of a-tocopherol (Sigma Chem. Go., product # T-3251 ) and 1.33 mmole of TEA in 3 ml of dry toluene was added (dropwise, under anhydrous conditions, while stirring) to 1.33 mmole of sebacoyl chloride 3 o dissolved in 2m1 of dry toluene. The reaction was carried out for 10 min at room temperature, followed by a dropwise addition of 2 mmole of PEG-600 (polyethylene glycol, Sigma, P-3390) and 2.66 mmole of TEA dissolved in 3 ml of toluene. The reaction was continued for additional 20 min at room temperature with constant stirring. The reaction mixture was extracted fourtimes with 3 ml each time of saturated solution of NaCI and toluene evaporated under a reduced pressure. The product was dissolved in 5 ml of water and the residual toluene was further removed by co-evaporation with water under a reduced pressure. The final waxy product (1.15 g) was obtained by lyophilization.
Other solubilizing agents (Table 1 ) were obtained by linking polyethylene 1o glycol (average molecular weight 1000, Sigma Chem. Co., product# P-3515) or methoxypolyethylene glycol (average molecular weight 750, Sigma Chem. Co., product # M-7018) to a-tocopherol using adipoyl, suberoyl, azelaoyl or dodecanedioyl dichlorides. They were synthesized according to the method of Example 2 and their identities were confirmed by mass spectrometry analysis z5 applying MALDI-TOF technique.
Example 3 provides molecular characteristics of the synthesized solubilizing agents.

Example 3. Molecular characteristic of solubilizing agents obtained by MALDI-TOF mass spectrometry.
Table 1. Molecular mass of synthesized solubilizing agents.
Solubilizing agent ~ Molecular mass mlz PSS-600 1194.3 44 PCS-600 1166.1 44 PTS-600 1209.7 44 PTD-600 1237.5 44 PTS-750Me 1355.7 44 PTD-750Me . 1383.7 44 PTS-1000 1605.9 44 PTSr-600 1181.6 44 PTSr-1000 1578.2 44 PTAz-600 1195.8 44 PTA-600 1153.5 44 PTSc-600 1125.7 44 PTS-400 1009.7 44 Example 4 illustrates a method of purification of solubilizing agents.
Example 4. Purification of solubilizing agents.
A solubilizing agent prepared according to Examples 1 or 2 was dissolved in water at 2:1 v/v ratio. The solution was heated in a boiling water bath for approximately 2 min, until a visible precipitation occurred. This was followed by a brief centrifugation (at least 2000xg) of the hot mixture to achieve separation of to the precipitated product which is insoluble in hot water. The water phase (supernatant ) was removed by decantation leaving a clear pellet of the product containing approximately 10% of water.
Examples 5 and 6 illustrate a preparation ofwater-soluble Coenzyme Q10 compositions by a direct admixing of the two components.
Example 5. Direct preparation of tocopherol-based water-soluble compositions of Coenzyme Quo.

Table 2. Components of tocopherol-based water-soluble Coenzyme Quo compositions .
Coenzyme Quo 0.01 g TPGS 0.035 g Coenzyme Quo 0.01 g PTS-600 0.03 g Coenzyme Quo 0.01 g PTD-600 0.03 g Coenzyme Quo 0.01 g PTS-750Me 0.03 g Coenzyme Quo 0.01 g PTD-750Me 0.03 g Coenzyme Quo 0.01 g PTS-1000 0.03 g Coenzyme Quo 0.01 g PTSr-1000 0.03 g Coenzyme Quo 0.01 g PTSr-600 0.03 g Coenzyme Quo 0.01 g PTAz-600 0.03 g Table 2 shows amounts of starting materials used for the preparation of a-tocopherol-based water-soluble compositions of Coenzyme Quo. In each case the two components were admixed together at a predetermined ratio and were heated to a temperature higher than fiheir melting points, typically 60°C-80°C, until the components melted together and formed a clear, transparent and uniform melt. The optimal ratio of a solubilizing agent to Coenzyme Quo was found to be 2:1 mol/mol or 3:1 w/w. These compositions could be stored in sealed vials for at least 2-3 years when refrigerated. They could be 2 o reconstituted at any time with water or physiological solution of saline (0.9%), at any ratio, and they remained wafer soluble and stable for several month when refrigerated or frozen.
Example 6. Direct preparation of sterol-based water-soluble compositions of Coenzyme Quo.
Table 3. Components of sterol-based water-soluble Coenzyme Quo compositions Coenzyme Quo 0.01 g PCS-600 0.03 g Coenzyme Quo 0.01 g PSS-600 0.03 g 2 o Table 3 shows amounts of starting materials used for the preparation of sterol-based, water-soluble compositions of Coenzyme Quo. In each case the two components were admixed at a predetermined ratio (the optimal ratio of a solubilizing agent to CoQ10 was found to be 2:1 mol/mol or 3:1 w/w) and were heated to a temperature higher than their melting points, typically 60°C-80°C, until the components melted together and formed a clear transparent liquid.
The liquid was dissolved in water (at a ratio 2:1 v/v) and the solution was heated in a boiling water bath for approximately 2 minutes, until clear waxy precipitate was formed. The precipitate could than be separated from the hot solution by centrifugation at 2000xg. To achieve its full water solubility at room temperature, the cycle of heating, centrifugation and cooling to room temperature, without removal of supernatant between the cycles, was repeated 2 to 3 times. After the final centrifugation, the hot supernatant was decanted and clear transparent pellet of the product was recovered. The compositions could be 2o stored refrigerated in sealed vials for at least 2-3 years. Aqueous solutions (in water or saline) of the above compositions could be prepared and they were stable for several months when refrigerated.
Examples 7, 8 and 9 illustrate preparation of water-soluble Coenzyme Q10 compositions in the presence of an auxiliary solvent.

Example 7. Solvent-based preparation of water soluble compositions of Coenzyme Quo.
Table 4. Components of water-soluble compositions of Coenzyme Quo.
Coenzyme Quo 5 g PCS-600 15 g THF 30 ml H20 400 ml Coenzyme Quo 0.01 g PSS-600 0.03 g THF 0.1 ml H20 2.5 ml Coenzyme Quo 0.3 g PTS-600 1 .0 g THF 4 .0 ml HBO 60.0 ml Coenzyme Quo 0.01 g PTD-600 0.03 g THF 0.1 ml H20 2.5 ml Coenzyme Quo 0.01 g PTS-750Me 0.03 g THF 0.1 ml H20 2.5 ml Coenzyme Quo 0.01 g PTD-750Me 0.03 g THF 0.1 ml H20 2.5 mi Table 4 shows amounts of starting materials used for various water-soluble Coenzyme Quo compositions. In each case Coenzyme Quo and a solubilizing agent were both dissolved in tetrahydrofuran (THF) and the solution was added to water with vigorous stirring, while maintaining the temperature of the mixture close to 0°C. The solvent and a part of water were then evaporated under a reduced pressure to obtain a desired concentration of Coenzyme Q'o, usually 80-100 mg /ml. These compositions could be stored refrigerated for at least 2-3 years and could be reconstituted with aqueous media (water, saline) to a desired final concentration of Coenzyme Quo in the water-soluble form.
1 o Compositions with higher concentrations of Coenzyme Quo (up to 200mg/ml) were also obtained by following this procedure.
Example 8. Solvent-based preparation of water-soluble TPGS - Coenzyme Quo composition.
Table 5. Components of water-soluble TPGS-Coenzyme Quo composition.
Coenzyme Quo 0.01 g TPGS 0.035 g THF 0.1 ml H20 2.5 ml Table 5 shows amounts of starting materials used for water-soluble 2o TPGS-Coenzyme Quo composition which was prepared according to the procedure described in Example 7. However, this product did not precipitated from an aqueous solution after heating. Water and the solvent could be removed by evaporation under a reduced pressure. Water solubility and stability of the composition was the same as those described in Examples 4 and 5.

Example 9 describes a procedure for the preparation of water-soluble ubiquinol compositions.
Example 9. Preparation of water-soluble ubiquinol compositions.
Table 6. Components of water-soluble ubiquinol compositions.
Ubiquino150 0.3 g TPGS 0.9 g Ubiquino150 0.3 g TPGS 0.9 g Propylene Glycol usp. 0.9 ml Ubiquinol 50 0.1 g Coenzyme Q~0 0.1 g PTS-600 0.5 g Ubiquinol 50 0.1 g Coenzyme Q~0 0.1 g Vitamin E 0.001 g PTS-600 0.5 g Table 6 shows amounts of starting materials used for water-soluble Zo ubiquinol (a reduced form of Coenzyme Quo) compositions. Ubiquinol was first prepared by the following method. 0.3 g of Coenzyme Quo and 0.2 g of zinc dust were suspended in 2.5 ml of glacial acetic acid. The mixture was placed in 50°C
water bath, with occasional shaking, for approximately 15 min. The reaction mixture was diluted with 2.5 ml of water and extracted twice with 5 ml of hexane.

The hexane extracts were combined, washed twice with 2.5 ml of wafer, dried over anhydrous magnesium sulfate, evaporated under reduced pressure and finally under a high vacuum. The resulting white waxy residue of ubiquinol was combined with 0.9 g of TPGS and it was heated to 60°C-80°C until the mixture melted and became clear. Upon reconstitution with water an opaque solution was formed. This composition remained unchanged for up to 2 months when sealed under argon and frozen. The water solubility of this composition could be improved by admixing with propylene glycol at a ratio given in the Table 6.
The aqueous (water and saline) solutions. of this composition were stable and could 1 o be stored sealed under argon when frozen.
Examples 10 and 11 illustrate preparation of water soluble vitamin E and ~-carotene compositions.

Example 10. Preparation of water-soluble formulations of vitamins.
Table 7. Components of water-soluble compositions of vitamin E and ~-carotene.
Vitamin E 0.10 g PTS-600 0.60 g Vitamin E 0.22 g PCS-600 1.00 g THF 2.50 ml H20 35.00 ml Vitamin E 0.025 g PTS-600' 0.150 g THF 0.125 ml H20 2.0 ml Provitamin A (~3-carotene) 0.01 g PTS-600 0.05 g THF 0.20 ml H2p 3.0 ml Table 7 shows amounts of starting materials used for various compositions prepared by direct admixing method (Example 5) orwith the aid of an auxiliary solvent (Example 7). The optimal ratio of a solubilizing agent to Vitamin E was found to be 2:1 mol/mol or 6:1 w/w. The concentrated compositions could be stored refrigerated for up to 2 years. The aqueous solutions (in water or saline) were also stable and could be stored frozen.
Example 11 illustrates methods for isolation, concentration and sterilization of the compositions according to the present invention.

Example 11. Isolation, concentration and sterilization of water-soluble compositions.
According to the present invention, two processes can be applied for the preparation of water-soluble compositions of lipophilic compounds: (i) a lipophilic compound and a solubilizing agent can either be combined directly and melted together, or (ii) the two are first dissolved in a water-miscible auxiliary solvent, the solution mixed with water and both the solvent and the excess of water are removed by evaporation. The obtained compositions are soluble in aqueous 1 o media at room temperature, but not at temperatures higher than approximately 80°C. They precipitate out of wafer when heated, but return to the solution upon cooling. This provides a simple, effective and inexpensive method of their isolation, concentration and sterilization.
2 ~ Typically, the aqueous solutions of the compositions (with the exception of TPGS-Coenzyme Quo, Example 9) are heated in a boiling water bath for about 2 min or until visible precipitate is formed. The separation of the precipitates from the hot water is accelerated by a rapid centrifugation at 2000xg. The water phase is decanted and the obtained waxy, transparent composition can be 2 o stored refrigerated in sealed vials. It remains stable for at least 8 month and can be further diluted with aqueous media (water, saline or a buffer). When refrigerated, these solutions are stable for at least 3 years. The process of precipitation/solubilization is reversible and repeating it several times improves the stability of diluted aqueous solutions of the composition. If precipitation of 25 the composition occurs during storage, its solubility can be restored by applying the above heating/centrifugation cycle. The compositions are also suitable for injections, since the described process can be applied for their sterilization.
Example 12 illustrates the preparation of dry powder compositions 3 o containing Coenzyme Quo.

Example 12. Preparation of dry powder Coenzyme Quo compositions.
Table 8. Components of dry powder Coenzyme Quo compositions.
CoQ10/PCS-600 composition containing0.07 g CoQ10/0.21 g PCS-600 40 mg of CoQ10/ml of water BSA (0.25 g/ml of water) 0.25 g CoQ10/PCS-600 composition 0.07 g CoQlO / 0.21 g PCS-600 containing 40 mg of CoQ10/ml of water Gelatin (0.125 g/ml in water) 0.25 g CoQ10/PCS-600 composition 0.03 g CoQ10 / 0.09 g PCS-600 containing 40 mg of CoQ10/ml of water Vitamin C (0.25 g/ml in water) 0:50 g Table 8 shows amounts of starting materials used for the preparation of dry powder compositions of Coenzyme QUO. The aqueous solutions of the above components were combined and lyophilized. The resulting powdered products could be pressed into tablets which remained stable and water-soluble.
Example 13 illustrates the preparation of dry powder compositions containing mu)tiple components.

Example 13. Preparation of compositions containing Coenzyme Quo, vitamin E and vitamin C.
Table 9. Components of water soluble complex compositions.
Coenzyme Q10/PTS-600 composition 0.03 g CoQ10 /0.09 g PTS-600 (containing 40 mg of CoQ10/ml of water) Vitamin E/PTS-600 composition (containing 20 mg of vitamin E/ml) ~ 0.005 g Vit E / 0.025 g PTS-600 Vitamin C (0.25 g/ml in water) ~ 0.75 g Table 9 shows amounts of starting materials used: The aqueous solutions of the above components were combined and lyophilized. The resulting powdered products could be pressed into tablets which remained stable and water-soluble.
Example 14 demonstrates the lack of toxicity of solubilizing agents.
Example 14. In vitro toxicity study.
Stock solutions of solubilizing agents (I mg/ml in PBS) were prepared and were added directly to lymphocytic Jurkat and neuroblastoma r~lT2 cell cultures in the amounts required to achieve a final concentration in the medium of 200, 100 and 50 mg/ml and cell viability was assessed by trypan blue exclusion 2 o assay. The results of assessment are shown in Fig. 1.
With the exception of commercially available TPGS, none of the solubiiizing agents of the invention had adverse effects on either cell growth or viability in vitro when added to cell cultures at concentrations up to 200 mg/ml.
Also. no toxicity was observed when the compositions containing CoQlO and PTS, PCS or PSS were given to Sprague Dawley rats at concentrations up to 20 mg/kg body weight, as shown in Fig.2.
Although no rationale can be provided to explain the toxicity of TPGS
observed in the experimental paradigm used, its usefulness as a solubilizing agent in pharmaceutical formulations should be further investigated and should 1 o be taken with caution.
Example 15 illustrates improved bioavailability of water-soluble forms of CoQ10.
15 Example 15. Bioavailability of water-soluble forms of Coenzyme Quo.
CoQ10, in the form of either water-soluble or oil-soluble compositions, was administered by gavage to 300-350 g male Sprague Dawley rats at a dose of 6mglkg body weight. Blood samples were collected and CoQ10 content was 2 o measured in plasma by the HPLC method which we have developed for analysis of CoQlO in biological samples (Graves et al., Analysis of CoEnzyme Q10 content in human plasma and other biological samples. In: Free Radicals and Antioxidant Protocols, Ed. D. Armstrong, Humana Press, pp: 353-365, 1998).
2 5 Briefly, 0.1 ml sample of plasma or lysed cells (Examples 15 and 16), was mixed with 0.33 ml of 1-propanol, vortexed for 30 sec and left to stand at room temperature for 1 min. 0.86 ml of n-hexane were than added, the sample was vigorously vortexed for 30 sec, and centrifuged to achieve a phase separation and to pellet the denatured proteins. The upper phase which consisted of n-3 o hexane and 1-propanol and contained CoQ~o was collected and evaporated to dryness under argon. The remaining dry residue was redissolved in 60 ml of ethanol and 2 ml of H202 in order to convert all. CoQ~o to its oxidized form.
Sample aliquots were analysed by a reverse-phase chromatography on a Supelcosil LC-18-DB column (5 mm particle size, 30 cm x4.0 mm I.D.,Supelco) with the mobile phase of ethanol:methanol 80:20 (v/v) at the flow rate of 1 ml/min. Absorbance at 275 and 290 nm was monitored.
A standard calibration curve of CoQ10 and Beckman System Gold Software were utilized for data quantification. The amount of Coenzyme Quo was calculated according to measured peak-areas of analysed samples. The z o calibration curve was prepared from a CoQ10 ethanol solution of a concentration determined spectrophotometrically from its extinction coefficient of E=14,200 at 275 nm. The ethanol solution of CoQ10 can be stored in sealed amber vials at -20°C.
The data presented in Fig. 2 show significantly improved (by 1.5 to 2 fold) bioavailability of CoQ10 when given orally as a water soluble compositions in comparison with the oil formulation. Significantly, the kinetics of the uptake is much faster (plasma level peaked at about 3 hr) and the maximal plasma levels achieved are also much higher (by 2 fold) when CoQ10 is given in the water soluble form.
Example 16 illustrates the ability of cells to internalize the water-soluble form of CoQ10.
Example 16 . Intracellular uptake of Coenzyme Quo.
The following experiments were designed to demonstrate the ability of human keratinocytes to internalize exogenous CoQ10. Human skin keratinocytes (ATCC CRL-8858), were cultured in SFM (serum free medium, Gibco BRL, cat 3o no. 10724) supplemented with 0.2 ng/ml of EGF (epidermal growth factor), 30 mg/ml of bovine pituitary extract and different concentrations of CoQ10 which was added directly to the tissue culture medium in a form of water soluble PCS
formulation. The cells were grown for up to 3 days under these conditions, then harvested and washed extensively. The cells (approximately 1- 3 x 106/ per sample) were resuspended in ddH20 and were broken by an osmotic shock after a freezing and thawing cycle. CoQ10 was extracted by a propanol/hexane solvent mixture and its content was measured by the HPLC described above.
In order to obtain the mitochondria) fraction, the cells were homogenized in a buffer containing 250mM sucrose, 50mM Tris-HCI pH 7.4, 5 mM MgCI~ and l0 1 mM EDTA. The homogenates were centrifuged at 800g for 10 min at 4°C.
The supernatants were collected and were further centrifuged at 10,OOOg for 10 min at 4°C. The pellets, representing crude mitochondria) fractions, were resuspended in 100 ml of ddH20, extracted with a propanol/hexane solvent mixture and processed for GoQ10 analysis.
TabIe10. Intracellular uptake of CoQ~o by cultured human keratinocytes.
CoQ~o added Total cellular CoQ~o content mglml of media ngl106 cells 0 - control 10 10 21.1 100 49.6 ~o The data summarized in Table 10 show the intracellular uptake of CoQ10 by human keratinocytes from the aqueous environment of tissue culture media.
During the 3-day experimental period the intracellular content of CoQlO
increased approximately 2-fold and 5-fold from the media containing 10 mg/ml and 100 mg/ml of CoQlO resuspended in the PCS formulation, respectively.
Table 11. Increased mitochondria) CoQ~o content in keratinocytes.
CoQ~o added Total cellular CoQ~o Total mitochondria) content mglml of ngl106 cells content media ngl106 cells 69 9.8 The results shown in Table 11 demonstrate a significant increase of CoQ10 content in the mitochondria) fraction of cells grown for 3 days in the presence of 10 mg/ml of CoQ10. It is expected that , in addition to its function as lipid-soluble antioxidant, the elevated CoQlO content, particularly in the mitochondria, will potentiate the efficiency of the energy producing respiratory chain which is pivotal for the cellular viability.
Example 17 serves to demonstrate the ability of CoQlO to increase the efficiency of mitochondria) respiratory chain to produce more ATP.

Example 17. Effects of Coenzyme Quo on cellular ATP content in human NT2 cells.
Human teratocarcinoma NT2 (Stratagene, San Diego, CA) were grown in DME medium (GiBco BRL) supplemented with 10 % FBS (fetal bovive serum) and 1 Omg/ml of CoQ10 which was added directly to the tissue culture medium in a form of water soluble PTS formulation. The cells were harvested at 24 hour intervals , resuspended in a buffer consisting of 0.02M glycine, 0.05M MgS04, so 0.004M EDTA, pH7.4 and aliquoted into 100pL samples.
The ATP content was measured using a luciferin-luciferase bioluminescence assay (Sigma, St. Louis MO). Luciferase catalyses the decarboxylation of luciferin and the hydrolysis of ATP to give pyrophosphate 15 and oxyluciferin. These reactions result in emission of light at 560nm. The intensity of the emitted light is proportional to the ATP concentration. The ATP
assay was carried out by mixing 100pL of sample with 75pL of a 0.5mg/mL
solution of luciferase-luciferin. Emitted light was detected using a Beckman LS
3801 scintillation counter. A standard curve was prepared ranging from 10 to 2 0 100 pmols of ATP. ATP levels were expressed as pmols ATP/pg protein.
Fig. 3 shows the effect of PTS-CoQlO composition on cellular ATP level in NY2 cells. The ATP level was reproducibly higher in cells that were cultured for 3 days in the presence of water soluble PTS-CoQ10 formulation. The data 25 points represent mean values from three separate experiments +/- SEM.
Example 18 shows protective effects of CoQ10 against hypoxia in human neuroblastoma NT2 cells.

Example 18. Protection against Hypoxia.
Human teratocarcinoma NT2 (Stratagene, San Diego, CA) were seeded info 25cm2 tissue culture flasks (at a density of 0.3 X 106 cells/ml) and were grown for 3 days in DME medium (Gibco BRL) supplemented with 10 % FBS
and in the presence or absence of either 10mg/ml of CoQ10-PTS formulation added directly to the tissue culture media. The flasks were sealed in an anaerobic chamber containing Gas Pak Plus gas generator envelopes and were incubated in the anaerobic conditions at 37°C for 17.5 hours in glucose-free ~ o medium. Following the hypoxic treatment the cells were placed again in the complete medium (with and without CoQ10 or vitamin E) and were analysed eifiher immediately (time 0) or were cultured for the additional 24 hr under the normoxic conditions. Cell viability was measured by trypan blue exclusion assay.
The results are shown in Fig. 4.
The protective effects of CoQ10 against hypoxia in NT2 cells is clearly evident. Approximately 50% less cells pre-treated for 3 days with PTs-Co010 died during the 24 hr recovery period from hypoxia as compared to the cells which did not receive CoQ10.
Example 19 shows that CoQ10 is equally effective in protecting cells against cell death triggered by hypoxia as vitamin E.
41.

Example 19. Comparison of Coenzyme Q10 and vitamin E anti-oxidant function.
Human teratocarcinoma NT2 (Stratagene, San Diego, CA) were seeded into 25cm2 tissue culture flasks (at a density of 0.3 X 106 cells/ml) and were grown for 3 days in DME medium (Gibco BRL) supplemented with 10 % FBS
and in the presence or absence of either 1 Omg/ml of CoQ10-PTS formulation or the same concentration of vitamin E-PTS formulation, which were added directly to the tissue culture media. The flasks were sealed in an anaerobic chamber so containing Gas Pak Plus gas generator envelopes and were incubated in the anaerobic conditions at 37°C for 17.5 hours in glucose-free medium.
Following the hypoxic treatment the cells were placed again in the complete medium (with and without CoQ10 or vitamin E) and were analysed either immediately (time 0) or were cultured for the additional 24 hr under the normoxic conditions. Cell viability was measured by trypan blue exclusion assay. The results are summarized in Fig. 5. .
In both experimental paradigms, the CoQ10 and Vitamin E treatments, the percentage of death during the 24 hr recovery period from hypoxia is 2 o reduced by half. This demonstrates that the protective effects of CoQ10 against hypoxia-induced cellular damage are comparable to those of vitamin E, the antioxidant with proven efficacy.
Example 20 demonstrates the protective effects of CoQ10 against 2 s ischemia/reperfiusion caused tissue damage. Although the animal model used is the experimental paradigm of human stroke, the data is relevant for any application where a tissue is damaged as a result of ischemia/reperfusion.

Example 20. Protective effects of CoQ10 against ischemialreperfusion.
Adult spontaneously hypertensive rats (SHR) weighting 225-250g , which readily develop stroke characteristic lesions after short periods of vessel occlusion, were used for the middle cerebral artery occlusion model (MCAO).
The anii~nals were anaesthetized and the right common carotid artery was permanently occluded. The skull was exposed and the right middle cerebral artery (MCA) was accessed through a 2 mm burr hole in the skull. Under a dissecting microscope a microclip was applied to the MCA vessel. After a 60 2 o min occlusion period, the clip was removed and the~wounds were closed. The body fiemperature was maintained throughout surgery and recovery at 37.5 °C
using a rectal thermistor probe connected to a heating lamp. CoQ10 (6 mg/kg) was administered intravenously (neck vein) immediately after the removal of the clip. The effects of 60 min ischemia were quantitated by tetrazolium salt TTC
z5 (2,3,5-triphenyl,2H-tetrazolium chloride) In order to quantitate the tissue damage, the brains were cut into 5mm coronal sections and were stained overnight with 2 % TTC. The coloured formazan was extracted using acetonitrile and its concentration was measured 2 o spectrophotometrically at 480 nm. The results as expressed as OD/g of dry brain tissue.

Table 12. Protective effects of CoQlO against ischemia-induced brain damage lJntreated animals ~ CoQ~o-treated animals Time Left brainRight brainTime after Left brainRight brain after hemispherehemisphere reperfusionhemispherehemisphere reperfu sion Sham 1250.0+/- 1239.0+I- sham 1250.0+/- 1239.0+/-31.8 11.9 31.8 11.9 1 day 1208.0+/- 1018.0+I- 1 day 1206.0+/- 1200.0+/-19.2 26.0 50.2 19.2 2 days 1104.0+l- 898.3+/-19.62 days 1084.9+/- 1060.9+/-36.2 22.2 21.2 Tetrazolium salts are histochemical indicators of mitochondrial respiratory enzymes and are used to detect tissue infarcts. TTC reacts with intact oxidative enzyme systems, such as succinate and NADH dehydrogenase, accepts Zo electrons and becomes reduced to a colored formazan which stains tissue red.
By contrast, irreversible damaged mitochondria that do not have intact oxidative system cannot reduce TTC and the tissue remains white unstained.
Accordingly, the healthier the tissue the higher the OD readings. Compare values obtained for brains of sham operated control rats ( approximately 1250 OD/ g of tissue) and for brains of experimental rats 898.3 OD/g tissue). The protective effects of CoQlO against ischemia-induced tissue damage are clearly evident, higher TTC content and, hence, the higher OD readings were obtained from brains of animals which received CoQ10-treatment postischemically Example 21 illustrate applicability and suitability of water soluble CoQ10 compositions in cosmetics.

Example 21. Water soluble CoQlO compositions in cosmetics.
Table 13. Preparation of cosmetics.
CoQ10-PCS-600 Classic Moisturizing Final CoQ10 Cream 100 mg/ml Oil of Olay concentration 1.5 ml 60 ml 0.25%

3.0 ml 60 ml 0.50%

CoQlO-PTS-600 Classic Moisturizing Final CoQ10 Cream 100 mg/ml Oil of Olay concentration 1.5 ml 60 ml 0.25%

3.0 ml 60 ml 0.50%

CoQ10-PTS-600 Dry Slcin Moisturizer Final CoQ10 100 mg/ml Pond's concentration ml 200 ml 0.25%

CoQ10-PTS-600 Moisturizing Body LotionFinal CoQlO

100 mg/ml Vaseline concentration 7.5 ml 300 ml 0.25%

CoQ10-PTS-600 Moisturizing Body LotionFinal CoQ10 100 mg/ml Oil of Olay concentration 5 ml 200 ml 0.25%

Table 13 shows amounts of starting materials used to prepare CoQlO-containing skin products which were combined according to the following procedure. The two components were mixed together at room temperature until they formed a uniform composition of a cream in which Coenzyme Q10 remained water soluble. This was tested by adding water to a 0.2 ml sample of cream (total volume of 1 ml). The samples were vigorously vortexed and centrifuged to separate phases. The aqueous phase remained yellow since it contained dissolved CoQ10. The creams were stable and no phase separation was observed even after several months at room temperature.
These cosmetics were tested on 20 healthy volunteers over one year period. All reported improved skin conditions, i.e. improved skin elasticity and reduction of wrinkles. None reported an adverse reaction.
Example 22 illustrates preparation of water soluble compositions containing polyene macrolide antibiotics.

Example 22. Preparation of compositions of anti-fungal antibiotics.
Table 14. Preparation of water-soluble formulations of anti-funga9 antibiotics.
Candicidin 0.01 g PCS-600 or PTS-600 0.02 g THF/H20 (8:2, v/v) 0.1 ml H20 2.5 ml Nystatin 0.01 g PCS-600 or PTS-600 0.02 g Glacial acetic acid 0.1 ml H20 2.5 ml Amphotericin B ' 0.01 g PCS-600 or PTS-600 0.02 g Methanol/Glacial acetic acid 0.3 ml (2:1, v/v) H20 2.5 m( Table 14 shows amounts of starting materials used to prepare water-soluble compositions of antibiotics. Antibiotics and solubilizing agents were dissolved separately in an appropriate solvent or solvent mixture. The solutions z o were combined and diluted with water. Solvents and excess of water were removed by evaporation under a reduced pressure. When glacial acetic acid was used as solvent, the co-evaporation with water was repeated several times.
Compositions containing 20 mg/ml of antibiotic were obtained by solvent evaporation. They were stable and could be stored frozen for extensive periods 15 of time (8 months). These compositions could be also isolated, further concentrated and sterilized by the technique described in Example 11. The final products were waxy, clear pellets which could be best stored frozen, in vials sealed under argon (up to 8 months). They could be reconstituted in aqueous media (water or saline) to desired concentrations.
Example 23 illustrates the preparation of water-soluble compositions containing polyene macrolide antibiotics.
Example 23. Preparation of water-soluble formulations of anti-fungal antibiotics io Table 15. Preparation of water-soluble formulations of anti-fungal antibiotics Amphotericin B, Nystatin 45 mg PCS-600, PTS-600 or PSS-600 135 - 180 Methanol/Glacial Acetic Acid (3:1 v/v) mg 6.0 ml 4.0 ml Table 15 shows the amounts of starting materials used forthe preparation of water-soluble compositions of antibiotics. The antibiotics and solubilizing agents (1 : 2 to 1: 4 w/w ratio) were dissolved directly in the solvent mixture(methanol/glacial acetic acid 3:1 v/v). The solvents were removed by evaporation under reduced pressure to obtain waxy residues. The residues were then dissolved in water, sterilized in boiling water bath for 5 min and were lyophilized to dryness. The final products were dry powders, which have been 2 o stored sealed under argon (for at least 1 year). They were reconstituted in water, saline or dextrose solution to a desired concentration. Typically, solutions containing 5 -30 mg/ml of antibiotics were obtained by this method. The aqueous solutions of Amphotericicn B were stable for at least 6 months at 4° C.
Examples 24 and 25 illustrate diminished toxicity of amphotericin B and Nystatin formulated according to the present invention.
Example 24. In vitro haemolysis of red blood cells(RBC) The haemolysis assay was performed using red blood cells (RBC) isolated from Balb/c mice. The blood was drawn in the presence of heparin (50 units/ml) , RBC were isolated and washed three times with phosphate-buffered saline (PBS). For the assay, 0.8 ml of 0.1 % RBC (vlv) in PBS were mixed with 0.2 ml of PBS buffer containing increasing concentrations of amphotericin B
(final concentrations from 0 to 200 p,g/ml), formulated with PSS, PCS and PTS
or to in the generic Fungizone. The mixtures were incubated at 37 °C for 1 h with gentle rotation. The samples were spun at 1000xg for 2 min. The content of haemoglobin in the supernatant was measured by absorbance at 541 nm. The amount of haemoglobin, released in the presence of 0.3% Triton X-100 during the same 1 h at 37 °C incubation period, was taken as a measure of 100%
haemolysis.
Table 16. Comparison of haemolytic activity of amphotericin B formulated with PSS, PCS
and PTS with the generic Fungizone.

Amphotericin Percentage B of Lysed (~,g/m!) Cells (mean value SEM)*

PSS - Amph PCS - Amph PTS - Amph Fungizo B B B ne 3:1 w/w 3:1 w/w 4:1 w/w 1 0 1.0 0.3 1.0 0.5 3.0 0.6 1 00.0 1.0 0.1 1.0 0.4 7.0 3.0 1 00.0 50 3.00.4 7.02.0 17.08.0 100.0 100 3.00.6 14.03.0 26.06.0 100.0 200 1.70.2 22.02.0 31.57.0 100.0 Note: * mean value ~ standard error of the mean of three separate experiments, each performed in duplicate According to the results presented in Table 16 all three formulations of amphotericin B, prepared according to the present invention, were far less toxic than the generic Fungizone. However, 10 ~,g/ml of amphotericin B in Fungizone caused 100% RBCs lysis during 1 hr incubation period, 200 ~g/ml of the antibiotic formulated with PSS lysed only 1.7% of the cells during the same time.
Example 25 In vitro haemolysis of red blood cells(RBC) Table.17.
Haemolytic activity of Nystatin formulated with PSS, PCS and PTS.

Nystatin Percentage of (~,g/ml) lysed Cells (mean value SEM)*

PSS - Nystatin PCS - NystatinPTS - NystatinTriton X-100 formulated at formulated formulated a ratio at a at a 2 :1 w/w ratio 2 : ratio 4 :
1 wlw 1 w/w 10 2.50.8 2.80.5 2.00.3 100.0 25 2.3 0.7 2.5 0.6 2.0 0.4 1 00.0 100 2.20.6 2.1 0.7 2.30.5 100.0 200 2.1 0.7 2.30.7 2.40.5 100.0 Note: * mean value ~ standard error of the mean of four separate samples.
As shown in Table 17 all three formulations of nystatin, prepared according to the present invention, were non-toxic within the concentration range of 10 to ~.g/ml.

Example 26 illustrates in vivo efficacy of the antibiotic formulations.
Example 26. Reduction of C. neoformans burden in mouse brain following 7-day treatment with amphotericin B formulated either with PCS or PTS
according to the present invention or with the generic Fungizone.
In vivo efficacy testing of amphotericin B formulations against systemic infection of murine Cryptococcus neoformans was performed on 8 weeks old female CD1 mice according to the following protocol. All animals were 1 o intravenously inoculated with 1.84 x 103 colony forming units (CFU) of C.
neoformans. Four days later the mice were subjected to a 7-day treatment regimen with either the generic Fungizone or amphotericin B -PCS, amphotericin B -PTS and PCS alone (vehicle). The antibiotic formulations were diluted with 5% dextrose to a final concentration of 250 p,g/ml and the mice received, intravenously, 0.2 ml/dose (equivalent to 2 mg/kg body weight) of the appropriate antifungal formulation. 24 hr after the last antifungal treatment, mice were killed and brains were harvested, homogenized and plated on SabDex agar. C. neoformans colonies were counted after a 3 day incubation at 26 °C.
2 o The infection burden of animals treated with the antimycotic agents was compared to the vehicle treatment.

Table 18.
C. neoformans infection burden in mice brain after 7-day treatment with amphotericin B - PCS, amphotericin B - PTS
and Fungizone Antimycotic Number Burden of C. neoformansInfection Statistical formulation of mice(mean Logo of CFU reduction analysis SEM) (n) (percentage) (p value) Fungizone 7 5.18 0.58 99.0 < 0.0001 Amph B-PCS 10 5.37 0.58 98.5 < 0.0001 Amph B-PTS 10 5.51 0.41 98.0 0.0003 Vehicle 8 7.18 0.30 0 (PCS alone) The data presented in Table 18 show that both amphotericin B formulations, prepared according to the present invention, significantly reduced the C.
neoformans burden in brains and that they were equally effective as the generic Fungizone.
Example 27 illustrates a release of free a-tocopherol into bloodstream following either oral or intravenous administration of PTS.
zo Example 27. Systemic release of vitamin E following administration of PTS
PTS, dissolved in water (50 mg/ml), was administered to Sprague Dawley s5 male rats (300-350 g) either orally or intravenously at a dose of 50 mg/kg body weight. Heparinized blood samples were collected at 0, 3, 8 and 24 hr following PTS administration. Blood plasma samples were obtained and analyzed forthe content of alpha-tocopherol using an HPLC method using a Supercosil LC-18-DB column and a mobile phase of ethanol:methanol (80:20 v/v) at a flow rate of 1 ml/min. Beckman System Karat software was used for~data quantification.
Table 19. Concentration of a-tocopherol in rat blood plasma following administration of PTS

Time Oral administration Intravenous (hours) (pg/ml) administration (pg/ml) 0 (control) 6.13 1.18 (n= 3) 6.13 1.18 (n=3) 3 8.65 1.40 (n=3) 18.48 2.40 (n=3) 8 9.33 2.10 (n=3) 11.19 3.11 (n=3) 24 8.31 0.60 (n=3) 10.59 1.48 (n=3) Elevated plasma content of a-tocopherol indicates a systemic conversion by the animal body, of PTS to active non-toxic vitamin E.
to Example 28 illustrates the ability to dissolve in water different oils with a high content of polyunsaturated fatty acids (PUFA) such as linoleic, linolenic, arachidonic eicosapentaenoic (EPA), docosahexaenoic (DHA) and their derivatives.
Example 28. Preparation of water-soluble formulations of oils containing PUFA
Oils were mixed directly with either PTS-600 or PSS-600 at a ratio 1:2 to 1:3 w/w. The mixture was then heated to a temperature of 40-50 °C to form a water-soluble composition in the form of a clear melt. The mixture was then diluted with water to form a solution. These water solutions of PUFA were stable for several months, when refrigerated.
Table 20. Preparation of water-soluble formulation of PUFA

Flaxseed oil, fish oil 1.0 g PTS-600, PSS-600 2.0 - 3.0 g Example 29 illustrates the ability to dissolve in water terpenes and terpenoids including: squalene, geraniol, farnesol, ~i-carotene, astaxanthin, canthaxanthin, zeaxanthin, cryptoxanthin, lutein and lycopene. Such compounds are useful as antioxidants, colorants and fragrances.
Example 29 Solubilization of terpenes and terpenoids Table 21. Preparation of water-soluble formulation of squalene Squalene 1.0 g PTS-600 , PCS-600, PSS-600 3.0 g The components are mixed directly with either PTS-600, PCS-600 or PSS-600, at a ratio 1:3 w/w. The mixture was then heated to a temperature of 40-50 °C to form a water-soluble composition in the form of a clear melt. The mixture was then diluted with water to form a solution. The solution is stable for several months, when refrigerated.

Table 22. Preparation of water-soiubie of astaxanthin Astaxanthin 0.005 g PTS-600 0.020 g THF 0.5 ml H20 5.0 ml Astaxanthin and PTS-600, in a weight ratio of 1:4, are dissolved in a water miscible solvent (THF) and the mixture is diluted with water to form an aqueous solution. The solution was then concentrated under a reduced pressure to remove the organic solvent and excess of water. The concentrated solution (2 mg/ml) was refrigerated and remained stable for several months.
Example 30 illustrates water solubilization of a-tocopheryl acetate.

Table 23. Preparation of water-soluble a-tocopheryl acetate a- tocopheryl acetate 0.10 g PTS-600 0.51 g THF 1.0 ml H2p 20.0 ml a- tocopheryl acetate 0.10 g PTS-400 0.43 g THF 2.0 ml H2p 20.0 ml a- tocopheryl acetate 0.10 g PTS-400 0.43 g a- tocopheryl acetate 0.10 g PTS-600 0.51 g a-tocopheryl acetate 0.10 g PTrienS-600 0.51 g (polyoxyethanyl--tocotrienyl sebacate) Table 23 shows amounts of starting materials used for various water-soluble formulations of a- tocopheryl acetate. The ratio of solubilizing agent to a- tocopheryl acetate was 2 :1 mol/mol or 4.5 : 1 w/w for PTS-400 and 5.5 : 1 w/w for PTS-600. Water-soluble formulations were obtained either with the aid of an auxiliary solvent or by the direct admixing method. The direct admixing was done at an elevated temperature of hot water bath (80-100° C). The mixture could be diluted with water to a desired concentration of a- tocopheryl acetate.

The aqueous solutions obtained by the direct admixing were slightly more opaque than the solutions obtained with the aid of auxiliary solvent. The solutions were stable when refrigerated.
Example 31 illustrates a method for the preparation polyoxyethanyl tocotrienyl sebacate (PTrienS).
Example 31. Synthesis of polyoxyethanyl tocotrienyl sebacate (PTrienS-600).
so 2.15 g of tocotrienols (NuTriene~, Eastmnan Chemical Company) and 0.925 ml of triethylamine (TEA) dissolved in 5 ml dry ethyl acetate were added dropwise to 1.45 ml of sebacoyl chloride, while stirring and under anhydrous conditions. The reaction was carried out for 5 min at room temperature, at which time 3 g of PEG-600 (polyethylene glycol, Sigma Chem. Co., product # P-3390) and 1.85 ml of TEA, dissolved in 5 ml of dry ethyl acetate, were added dropwise while cooling in an ice bath. The reaction was continued with constant stirring for an additional 5 min at room temperature. The reaction mixture was extracted four times with 5 ml (each time) of a saturated solution of NaCI. The reaction product remained soluble in the organic phase from which ethyl acetate was z o removed under reduced pressure, leaving a waxy residue of the product. The product was further dissolved in 50 ml of methanol and the methanol-insoluble by-products were removed by centrifugation, and methanol was evaporated under reduced pressure. The solid waxy product was dissolved in 20 ml of water and lyophilized, yielding approximately 1.3 g of brownish -waxy solid of PTrienS
2 5 600.
Example 32 illustrates water solubilization of tocotrienols.
Example 32 water solubilization of tocotrienols Table 24, Preparation of water-soluble tocotrienols NuTriene 0.1 g PTS-600 0.56 g THF ~ 1.0 ml H20 30 m( NuTriene 0.1 g PTS-600 0.56 g NuTriene 0.1 g PTrienS-600 0.56 g Table 24 shows amounts of starting materials used for various water-soluble formulations of tocotrienols. The ratio of solubilizing agent to tocotrienols was about 2 :1 mol/mol or 5.5 : 1 w/w. Water-soluble formulations were obtained either with the aid of an auxiliary solvent or by the direct admixing method. The direct admixing was done at elevated temperature of hot water bath (80-100° C). The mixfiure was diluted with water to a desired concentration of tocotrienols. The aqueous solutions obtained with PTS were opaque, whereras the solution obtained with PTrienS was clear. The solutions were s o stable when refrigerated.
Example 33 illustrates water solubilization of Coenzyme Quo in PTrienS-600 and PTS-400.
Example 33. Preparation of water-soluble formulations of Coenzyme Quo Table 25. Preparation of water-soluble Coenzyme Quo Coenzyme Quo 0.012 g PTS-400 0.028 g Coenzyme Quo 0.010 g PTrienS-600 0.035 g Table25 shows amounts of starting materials used to prepare water-soluble formulations of Coenzyme Quo. The ratio of Coenzyme Quo to PTS-400 was 1: 2.5 w/w and to PtrienS-600 1:3.5 w/w. The formulations were obtained by a direct admixing at elevated temperature of hot water bath (80 -100° C).
The mixture was diluted with water to a desired concentration of Coenzyme Quo .
The aqueous solutions were stable when refrigerated.

Claims (43)

CLAIMS:

1. A method for the treatment of a fungal infection in humans or warm-blooded animals in need of such treatment, comprising administering to such human or warm-blooded animal, a therapeutically effective amount of a water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-.alpha.-tocopheryl sebacate, and a macrolide polyene antibiotic, formulated in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1, in conjunction with a pharmaceutically effective carrier or excipient.

2. A method according to Claim 1, wherein the anitibiotic is selected from the group consisting of amphotericin B and nystatin.

3. A method according to Claim 1, wherein the antibiotic is amphotericin B, and wherein the weight ratio of solubilizing agent to antibiotic is 3:1 to 4:1 w/w.

4. A method according to Claim 1, wherein the antibiotic is nystatin, and wherein the weight ratio of solubilizing agent to antibiotic is 2:1 to 4:1 w/w.

5. A water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-.alpha.-tocopheryl sebacate, and a macrolide polyene antibiotic, formulated in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1.

6. A composition according to Claim 5, wherein the antibiotic is selected from the group consisting of amphotericin B and nystatin.

7. A composition according to Claim 5, wherein the antibiotic is amphotericin B, and wherein the weight ratio of solubilizing agent to antibiotic is 3:1 to 4:1 w/w.

8. A composition according to Claim 5, wherein the antibiotic is nystatin, and wherein the weight ratio of solubilizing agent to antibiotic is 2:1 to 4:1 w/w.

9. A composition according to Claim 7, wherein the solubilizing agent is polyoxyethanyl-sitosterol sebacate.

10. A composition according to Claim 7, wherein the solubilizing agent is polyoxyethanyl-cholesteryl sebacate.

11. A composition according to Claim 7, wherein the solubilizing agent is polyoxyethanyl-.alpha.-tocopheryl sebacate.

12. A composition according to Claim 8, wherein the solubilizing agent is polyoxyethanyl-sitosterol sebacate.

13. A composition according to Claim 8, wherein the solubilizing agent is polyoxyethanyl-cholesteryl sebacate.

14. A composition according to Claim 8, wherein the solubilizing agent is polyoxyethanyl-.alpha.-tocopheryl sebacate.

15. A method for preparing a water soluble composition according to Claim 5, which method comprises the steps of, (e) dissolving the antibiotic and the solubilizing agent in a water-miscible organic solvent, in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1, (f) removing from the solution the organic solvent to achieve a desired concentration of the water soluble composition, (g) dissolving the composition in water, and (h) drying.

16. A method according to Claim 15, wherein the antibiotic is amphotericin B, and wherein the weight ratio of solubilizing agent to antibiotic is 3:1 to 4:1 w/w.

17. A method according to Claim 15, wherein the antibiotic is nystatin, and wherein the weight ratio of solubilizing agent to antibiotic is 2:1 to 4:1 w/w.

18. A method according to Claim 15, wherein the solvent is methanol/acetic acid 3:1 v/v.

19. A method for delivery of .alpha.-tocopherol to humans or warm-blooded animals in need thereof, comprising administering to such human or warm-blooded animal, an effective amount of a water-soluble form of vitamin E.

20. A method according to Claim 19, wherein the water-soluble form of vitamin E is polyoxyethanyl-.alpha.-tocopheryl sebacate.

21. A water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-.alpha.-tocopheryl sebacate, and a compound having a high content of polyunsaturated fatty acids.

22. A composition according to Claim 21, wherein the compound is an oil, and wherein the solubilizing agent and oil are formulated in a weight ratio of solubilizing agent to oil of 2:1 to 3:1.

23. A composition according to Claim 22 wherein the oil is selected from the group consists of flaxseed oil and fish oil.

24. A water-soluble, composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-.alpha.-tocopheryl sebacate, and a bioactive lipophilic compound selected from the group consisting of a terpene and a terpenoid.

25. A composition according to Claim 24, wherein the solubilizing agent and bioactive compound are formulated in a weight ratio of solubilizing agent to bioactive compound of 3:1 to 4:1.

26. A composition according to Claim 25, wherein the bioactive lipophilic.
compound is selected from the group consisting of squalene, geranoil, farnesol, .beta.-carotene, astaxanthin, canthaxanthin, zeaxanthin, cryptoxanthin, lutein and lycopene.

27. A composition according to Claim 25, comprising polyoxyethanyl-.alpha.-tocopheryl sebacate and squalene, in a weight ratio of polyoxyethanyl-.alpha.-tocopheryl sebacate to squalene of 3:1.

28. A composition according to Claim 25, comprising polyoxyethanyl-.alpha.-tocopheryl sebacate and astaxanthin, in a weight ratio of polyoxyethanyl-.alpha.-tocopheryl sebacate to astaxanthin of 4:1.

29. A method for preparing a water-soluble composition according to Claim 28, comprising:
a) dissolving solubilizing agent and astaxanthin in a water-miscible organic solvent, in a weight ratio of solubilizing agent to astaxanthin of 4:1 to form a mixture;
b) diluting the mixture with water to form an aqueous solution;
c) concentrating the aqueous solution to remove the organic solvent and excess of water;

30. A method according to Claim 29, wherein step c) is effected by evaporation under reduced pressure.

31. A water-soluble composition, comprising polyoxyethanyl-.alpha.-tocopheryl sebacate and .alpha.-tocopheryl acetate, formulated in a ratio of 2:1 to 5.5:1 w/w.

32. A composition according to Claim 31, comprising PCS-400 and .alpha.-tocopheryl acetate, formulated in a ratio of PCS-400 to .alpha.-tocopheryl acetate of 2:1 to 4.5:1 w/w.

33. A composition according to Claim 31, comprising PCS-600 and .alpha.-tocopheryl acetate, formulated in a ratio of PCS-600 to .alpha.-tocopheryl acetate of 5.5:1 w/w.

34. A water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-.alpha.-tocopheryl sebacate and polyoxyethanyl tocotrienyl sebacate, and a tocotrienol, formulated in a ratio of solubilizing agent to tocotrienol of about 5.5:1 w/w.

35. A composition according to Claim 34, wherein the solubilizing agent is PTS-600.

36. A composition according to Claim 34, wherein the solubilizing agent is PtrienS-600.

37. A water-soluble composition, comprising a solubilzing agent selected from the group consisting of polyoxyethanyl-.alpha.-tocopheryl sebacate and polyoxyethanyl tocotrienyl sebacate, and coenzyme Q10, formulated in a ratio of solubilizing agent to coenzyme Q10 of 2.5:1 to 3.5:1 w/w.

38. A composition according to Claim 36, wherein the solubilizing agent is PTS-400, and wherein the ratio of PCS-400 to coenzyme Q10 is 2.5:1 w/w.

39. A composition according to Claim 36, wherein the solubilizing agent is PtrienS-600, and wherein the ratio of PtrienS-600 to coenzyme Q10 is 3.5:1 w/w .2.5:1 w/w.

40. A water-soluble composition comprising a bioactive lipophilic compound and a solubilizing agent of the general formula {X-OOC-[(CH2)n-COO]m}p-Y
wherein: p is 1 or 2, m is 0 or 1, and n is an integer in the range O <= n <= 18 X is a residue of a hydrophobic moiety selected from the group consisting of cholesterol, 7-dehydrocholesterol, campesterol, sitosterol, ergosterol, stigmasterol, and .alpha.-,.beta.-, y-, and .DELTA.-tocopherols and derivatives thereof, Y is a residue of a hydrophilic moiety, selected from the group consisting of polyalcohols, polyethers, polyanions, polycations, polyphosphoric acids, polyamines, polysaccharides, polyhydroxy compounds, polylysines and derivatives thereof, provided that:
when p and m are equal to 1 and the hydrophobic moiety is (+)-a-tocopherol, n is not equal,to 2.

41. A composition according to claim 39, wherein the bioactive lipophilic compound is selected from the group consisting of ubiquinones, ubiquinols, vitamins, provitamins, polyene macrolide antibiotics, and mixtures thereof , provided that:
when the bioactive lipophilic compound is ubiquinone and the hydrophobic moiety is cholesterol, n is not equal to 8.

42. A composition according.to Claim 39, where the hydrophilic moiety is PEG-400.

43. A method for making polyoxyethanyl tocotrienyl sebacate, comprising:
a) dissolving a tocotrienol in an organic solvent, b) reacting the solution with a compound of the general formula Z-OC-(CH2)n-CO-Z, where Z is a leaving group, and c) reacting with a compound of the general formula HO-Y-OR, wherein R is hydrogen or an alkyl, and n is from 0 to 18.